XRCC1 functions as a non-enzymatic, scaffold protein in single strand break repair (SSBR) and base excision repair (BER). Here, we examine different regions of XRCC1 for their contribution to the scaffolding functions of the protein. We found that the central BRCT1 domain is essential for recruitment of XRCC1 to sites of DNA damage and DNA replication. Also, we found that ectopic expression of the region from residue 166-436 partially rescued the methyl methanesulfonate (MMS) hypersensitivity of XRCC1-deficient EM9 cells, suggesting a key role for this region in mediating DNA repair. The three most common amino acid variants of XRCC1, Arg194Trp, Arg280His and Arg399Gln, are located within the region comprising the NLS and BRCT1 domains, and these variants may be associated with increased incidence of specific types of cancer. While we could not detect differences in the intra-nuclear localization or the ability to support recruitment of POLβ or PNKP to micro-irradiated sites for these variants relative to the conservative protein, we did observe lower foci intensity after micro-irradiation and a reduced stability of the foci with the Arg280His and Arg399Gln variants, respectively. Furthermore, when challenged with MMS or hydrogen peroxide, we detected small but consistent differences in the repair profiles of cells expressing these two variants in comparison to the conservative protein.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319167 | PMC |
http://dx.doi.org/10.1016/j.dnarep.2012.01.001 | DOI Listing |
Pediatr Radiol
January 2025
Diagnostic and Interventional Radiology Department, Hospital for Sick Children, 555 University Ave, Toronto M5G 1X8, Toronto, Canada.
Background: Hepatocellular adenomas (HCAs) are rare, benign hepatic tumors in children, with limited imaging data available for pediatric cases.
Objective: To describe the magnetic resonance imaging (MRI) and clinical features of histologically proven HCAs in children.
Materials And Methods: Single-center retrospective review of pathology-proven HCA from January 2004 to February 2024.
Clin Exp Dent Res
February 2025
Department of Prosthodontics, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Objectives: Temporomandibular disorder (TMD) encompasses various clinical issues affecting the temporomandibular joint, masticatory muscles, and surrounding structures. Common symptoms include pain, joint and muscle tenderness, and limited jaw movement. Diverse treatment options have been utilized to manage TMD.
View Article and Find Full Text PDFHemodial Int
January 2025
DaVita Patient Safety Organization, Denver, Colorado, USA.
Introduction: Chronic kidney disease-mineral and bone disorder (CKD-MBD), is a common syndrome in end stage kidney disease (ESKD) patients, is marked by dysregulation of electrolytes and hormones, including calcium, phosphorus and parathyroid hormone (PTH). Calcimemetics are a cornerstone of PTH lowering therapy; cinacalcet, an oral calcimemetic, is the most used and typically prescribed as a daily administration, thus contributing to the high total pill burden of this population. Recent clinical trials have provided evidence that administration of cinacalcet at the dialysis unit three times a week might be a safe and effective treatment option.
View Article and Find Full Text PDFTranspl Infect Dis
January 2025
Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Background: Infections are a common complication among lung transplant recipients (LuTR), particularly in the first year post-transplant, with respiratory tract infections (RTI) being predominant. Syndromic molecular panels have been suggested to reduce morbidity and mortality by providing a diagnosis quickly. However, integrating these panels into clinical practice remains debated.
View Article and Find Full Text PDFEur J Haematol
January 2025
Department of Research & Development, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.
Comprehensive insights are lacking into why patients with hematological malignancies (HMs) receive no cancer-directed treatment. We evaluated socio-demographic and cancer-related characteristics, decision-making rationales, and overall survival in patients with three common HMs-diffuse large B-cell lymphoma (DLBCL), symptomatic multiple myeloma (MM), and acute myeloid leukemia (AML)-who do not receive cancer-directed treatment, using the nationwide Netherlands Cancer Registry. A total of 26 945 patients diagnosed with DLBCL (47%), symptomatic MM (29%), or AML (25%) between 2014 and 2021 were included.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!